subscribe now
Not getting email updates?
February 14, 2018

Rx Pipeline Update Q1 2018

Learn what medications are in development and how their expected approval will impact care

EnvisionRx continuously monitors the drug pipeline and keeps an eye on new drugs in development that will profoundly impact care. Our Rx Pipeline Update provides information on those medications that are nearing approval, sharing differentiators and impactful drug details, to help you prepare for the future. The following are drugs you should be aware of:

Antidote for oral anticoagulants
Andexanet alfa
 - Prior to the development of andexanet alfa, there were not any products available to directly reverse the actions of Factor Xa inhibitors. This IV-infused medication would offer an antidote for major bleeds due to Factor Xa anticoagulation. 


HIV
Bictegravir/emtricitabine/tenofovir alafenamide
- Bictegravir (50mg) (BIC), a novel integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) will offer a treatment of HIV-1 infection in treatment-naive adults. This fixed dose combination will provide patients with another option for simple, convenient dosing.

*During publication, this drug was granted FDA approval and will be marketed as Biktarvy.

Ibalizumab - Ibalizumab, a humanized monoclonal antibody, if accepted by the Food and Drug Administration (FDA), will be the first HIV therapy with a new mechanism of action to be approved in nearly ten years. This treatment will offer a new add-on option for those patients with multi-drug resistant HIV. After the IV-infused loading dose, ibalizumab should be administered every two weeks, which offers the first infrequent adjunct therapy.


Cystic Fibrosis
Tezacaftor/ivacaftor
- Tezacaftor/Ivacaftor is a combination product for patients with cystic fibrosis. This two-drug combination approval is a key step for Vertex Pharmaceuticals to eventually reach a three-drug therapy, impacting a greater cystic fibrosis population. 


Plaque Psoriasis
Tildrakizumab
- Merck’s IL-23 inhibitor will be joining a crowded market of biologics for plaque psoriasis if it gains FDA approval, which is anticipated in March 2018.

 

Pipeline Updates Blog Banner Q1 1900w.jpg

 

Related